MET and non-small cell lung carcinoma: The next step in the development of the combination tested by SAVANNAH and SAFFRON trials is the initiation of a double-blind, multicenter phase III randomized SANOVO trial [96], which aims to assess the combination of osimertinib with savolitinib versus osimertinib in first-line treatment of EGFR-mutated advanced NSCLC patients with MET alterations with the hypothesis that the combination strategy would delay progression.